News

Why Is Replimune Stock Trading Lower On Monday?
Replimune stock falls as FDA denies skin cancer drug approval and investors sue over alleged misstatements tied to the IGNYTE ...
Health Check: Audeara strives to be ‘the next Cochlear’ in affordable hearing collab
Cochlear’s Baha devices – as in bone-anchored hearing aid – cost around $10,000 locally. Strictly speaking, the $4 million ...
InvestorsHub on MSN2d
Replimune Shares Slide as FDA Dispute Over Cancer Drug Approval Comes to Light
Shares of Replimune Group Inc. (NASDAQ:REPL) plunged 36% in premarket trading after a report revealed new details about the ...
Replimune stock plunges after FDA cancer drug rejection details emerge
The rejection occurred amid broader turmoil at the FDA, which has been experiencing leadership changes, staff upheaval, and internal dysfunction. These organizational issues reportedly factored into ...
Replimune down as FDA’s top cancer drug regulator reportedly intervened in drug rejection
Replimune (REPL) stock plummets as report suggests FDA’s top regulator of cancer drugs intervened in rejecting its lead asset ...
STAT2d
FDA’s top cancer drug regulator played key role in rejection of Replimune therapy, officials say
The FDA's top regulator of cancer drugs played a key role in the rejection of a skin cancer therapy from Replimune Group, ...
The Daily Reflector4d
Bragar Eagel & Squire, P.C. Is Reminds Investors of Class Actions Against Neogen, Alto,
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf ...
Targeted Oncology5d
July's Oncology Approvals: A Landmark Month for Cancer Treatment Advancements
July marks a transformative month in oncology with the FDA's groundbreaking approvals and updates, enhancing treatment ...
Stocktwits on MSN6d
Replimune Stock Catches Retail Fire As Analyst Says FDA Shakeup Removes 'Major Obstacle' For Skin Cancer Drug's Potential Approval
Retail trader buzz around Replimune Group surged Wednesday after Cantor Fitzgerald upgraded the stock to ‘Overweight’ from ...